


## Australia offers revolutionary new treatment for antibiotic resistance

12 February 2021 | News

**A revolutionary new treatment that involves the revitalization of a well-known antibiotic to enter clinical trials in Australia this year**



SuperTrans Medical (STM), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacteria, has published First-In-Class, successful pre-clinical results and announced plans to begin clinical trials in Australia later this year for its lead candidate STM-001.

Offering new hope in the plight against antimicrobial resistance (AMR), STM has applied its patented permeator technology to the widely used antibiotic vancomycin through a process of "intelligent repurposing". The technology, originally developed at Stanford University, attaches easily to the existing antibiotic. The modified antibiotic can effectively penetrate into urgent threat bacterial pathogens allowing a highly effective eradication of superbugs.

The lead indication for STM-001 has been confirmed as Urinary Tract Infections (UTIs), following exceptional results in pre-clinical studies and given the urgent need for better antibiotic alternatives for complicated UTIs. Selection for this clinical indication is based on compelling proof-of-concept data in a challenging animal model of *E. coli* infection to be published in the April issue of *Antimicrobial Agents and Chemotherapy* (AAC). [Manuscript](#)

"Our pre-clinical data has already shown STM-001 is effective within a broad therapeutic window and we are now working towards initiating Phase 1 clinical trials in Australia later this year" says Dr Neville CEO, SuperTrans Medical.

The STM-001 clinical trial in healthy volunteers is expected to commence late in the 2021 calendar year in Australia.

### ***STM's Permeator Technology***

SuperTrans Medical is developing novel antibiotics through the use of its unique Guanidinium-Rich Molecular Transporter (GR-MoTr) technology. The permeator unit can be easily attached (conjugated) to existing approved antibiotics, resulting in a revitalised drug with superior anti-microbial properties. The permeator component of the antibiotic conjugate exerts a dual role to allow improved docking of the drug at the outer bacterial membrane as well as serving as a molecular "drill" to breach the membrane. Consequently, therapeutic intra-bacterial concentrations are generated which drive a rapid and complete bacterial eradication.